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Abstract 
Background: In Cambodia, elimination of artemisinin resistance through direct elimination of the Plasmodium falci-
parum parasite may be the only strategy. Prevalence and incidence at district and village levels were assessed in Chey 
Saen district, Preah Vihear province, North of Cambodia. Molecular and clinical indicators for artemisinin resistance 
were documented.
Methods: A cross sectional prevalence survey was conducted at village level in the district of Chey Saen from Sep‑
tember to October 2014. Plasmodium spp. was assessed with high volume quantitative real‑time polymerase chain 
reaction (qPCR). Plasmodium falciparum‑positive samples were screened for mutations in the k13‑propeller domain 
gene. Treatment effectiveness was established after 28 days (D28) using the same qPCR technique. Data from the 
provincial surveillance system targeting symptomatic cases, supported by Médecins Sans Frontières (MSF), were used 
to assess incidence.
Results: District P. falciparum prevalence was of 0.74 % [0.41; 1.21]; village prevalence ranged from 0 to 4.6 % [1.4; 
10.5]. The annual incidence of P. falciparum was 16.8 cases per 1000 inhabitants in the district; village incidence ranged 
from 1.3 to 54.9 for 1000 inhabitants. Two geographical clusters with high number of cases were identified by both 
approaches. The marker for artemisinin resistance was found in six samples out of the 11 tested (55 %). 34.9 % of qPCR 
blood analysis of symptomatic patients were still positive at D28.
Conclusions: The overall low prevalence of P. falciparum was confirmed in Chey Saen district in Cambodia, while 
there were important variations between villages. Symptomatic cases had a different pattern and were likely acquired 
outside the villages. It illustrates the importance of prevalence surveys in targeting interventions for elimination. 
Mutations in the k13‑propeller domain gene (C580Y), conferring artemisinin resistance, were highly prevalent in both 
symptomatic and asymptomatic cases (realizing the absolute figures remain low). Asymptomatic individuals could be 
an additional reservoir for artemisinin resistance. The low effectiveness of dihydroartemisinin–piperaquine (DHA–PPQ) 
for symptomatic cases indicates that PPQ is no longer able to complement the reduced potency of DHA to treat falci‑
parum malaria and highlights the need for an alternative first‑line treatment.
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Background
Since 2000, huge efforts in malaria control have resulted 
in a 47 % decrease in malaria-associated mortality world-
wide and in a 30 % decrease in incidence of malaria [1]. 
Unfortunately, these achievements are threatened by the 
emergence and spread of Plasmodium falciparum resist-
ance to artemisinin and partner drugs. Current efforts to 
contain artemisinin resistance, consisting of a wide range 
of activities, such as long-lasting insecticide-treated net 
campaigns, implementation of accurate and widely-
available malaria rapid diagnostic tests (RDT), banning 
of artemisinin monotherapies, and universal access to 
artemisinin-based combination therapy (ACT) [2], have 
yet to show success. Elimination of artemisinin resistance 
through direct elimination of the P. falciparum parasite 
may be the only present strategy [3].
In low transmission settings, the human asymptomatic 
and/or microparasitaemic reservoir is an important chal-
lenge in the context of malaria and artemisinin resistance 
elimination, as this reservoir typically escapes routine 
surveillance, but can contribute to active transmission 
[4, 5]. However, successful attempts to identify and quan-
tify the asymptomatic reservoir have only rarely been 
documented.
Artemisinin resistance has been reported in Western 
Cambodia since 2008 [6–9]. Artemisinin resistance is 
defined as delayed parasite clearance, which represents 
a partial resistance. Recently, a molecular marker of 
artemisinin resistance was identified. Mutations in the 
Kelch 13 (k13)-propeller domain (especially C580Y) were 
shown to be associated with delayed parasite clearance 
in  vitro and in  vivo [10]. In 2013, Médecins Sans Fron-
tières (MSF) in collaboration with the Ministry of Health 
initiated a programme for the elimination of P. falci-
parum in Chey Saen district, Preah Vihear province, in 
the North of Cambodia, a region with documented arte-
misinin resistance. This programme included two succes-
sive prevalence surveys (relying on molecular methods 
for the identification of asymptomatic carriers and of 
individuals carrying resistant parasite strains), and sup-
port and scale-up of the passive case detection network 
(relying on a strong collaboration with the public sec-
tor—Health Centers, Health Posts, Village Malaria Work-
ers, and Malaria Contact Persons identified in important 
plantations and settlements—and the registered private 
sector in the district). Considering the dearth of informa-
tion on the performance of surveys and routine surveil-
lance in low malaria transmission settings, the objective 
of this study was (i) to document the prevalence and 
incidence of Plasmodium spp. and P. falciparum at dis-
trict and village level in Chey Saen district, as assessed 
through respectively a prevalence survey and a passive 
case detection system (the aim was to be able to target 
villages with higher transmission and indicators of resist-
ance), and (ii) to document the molecular and clinical 




The study was conducted across all villages of the dis-
trict of Chey Saen, Preah Vihear province, located in the 
North of Cambodia, bordering Thailand and the Lao 
People’s Democratic Republic. The district consisted 
of 21 villages, with two sub-villages considered as inde-
pendent from the main village, resulting in 23 geographi-
cal units included in the study. The district population 
consisted of 22,343 individuals in 4585 households, and 
village sizes ranged from 328 to 2016 inhabitants (67–397 
households). The study concerned the entire district pop-
ulation, but did not cover workers from a major Chinese 
company in the district, as access to this population was 
not possible.
Study period
The prevalence study was conducted in September and 
October 2014. The study period for the passive case 
detection covered June 2014 to May 2015.
Study population and sample size
For the prevalence survey, random sampling was done 
from the entire district population (a population census 
was done prior to the survey); children less than 1  year 
were excluded. Sample sizes were calculated per village, 
with an assumed P. falciparum prevalence of 7 %, a con-
fidence of 95 %, a precision of 5 %, and a correction for 
finite populations based on each village size. If the target 
sample size for a village was not reached, a second sam-
pling was done. To minimize absenteeism, participants 
were given an incentive for their participation (krama, a 
piece of local fabric).
For the passive case detection (PCD) component, all 
individuals presenting with fever and/or other malaria 
symptoms (headache, fatigue, body pain, nausea, etc.), 
in the public and private registered sector were included. 
Unregistered private providers were not included in 
Keywords: Malaria, Plasmodium falciparum, Epidemiology, Artemisinin resistance, Polymerase chain reaction,  
k13‑propeller, Cambodia
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the surveillance system. Private providers were mapped 
through consultative meetings with the village chiefs, 
community elders, and representatives of the private 
sector.
Prevalence survey—methodology
For each participant of the prevalence survey, 3  ml of 
whole blood was drawn (0.5  ml for children less than 
5 years of age) in EDTA tubes. Samples were centrifuged 
within 24 h to separate plasma and buffy coat, stored in a 
freezer (−20 °C), and transported to the Malaria Molecu-
lar laboratory at Mahidol University, Bangkok, Thailand, 
in cold chain. For each sample, high volume quantitative 
real-time PCR (qPCR) was performed, with a detection 
limit of 22 parasites per millilitre [11]. Samples were 
lysed in protease-containing buffer, and DNA extraction 
was performed using the QIAamp Blood Midi Kit (Qia-
gen). For samples containing parasite DNA, Plasmodium 
species detection was attempted using PCR protocols 
specific to detect the 18S rRNA gene of Plasmodium 
spp. Samples for which Plasmodium species could not 
be determined were reported as Plasmodium species. 
In each screening run, controls assessing both the DNA 
extraction and the PCR steps were included (extraction/
PCR process, cross contamination and reagents).
Plasmodium falciparum-positive samples were 
screened for mutations in the k13-propeller domain 
gene, a molecular marker associated with artemisinin 
resistance [12]. Purified PCR products were sequenced 
at Macrogen, Republic of Korea (BioEdit v. 7.1.3.0., using 
the 3D7 kelch13 sequence as reference). The definition of 
single nucleotide polymorphisms (SNPs) was based on 
analytical approaches described previously [13, 14].
Passive case detection—methodology
Case detection in the public—health facilities and vil-
lage malaria workers (VMW)—and private sector 
was done by rapid test. The public sector used the 
First Response Malaria Ag. pLDH/HRP2 Combo Card 
Test (Premier Medical Corporation Limited, India till 
December 2014 and switched to SD BIOLINE Malaria 
Ag P.f/P.v (Standard Diagnostics, Korea) in 2015. The 
private sector usually relied on First Response Malaria or 
Malacheck (Standard Diagnostics, Korea). P. falciparum-
positive cases (mono-infections and mixed infections) 
received dihydroartemisinin (DHA) and piperaquine 
(PPQ) (Eurartesim®, Sigma Tau, Italy) for 3 consecu-
tive days (first dose under supervision, dosage accord-
ing to national guidelines), and were tested for G6PD 
deficiency using the G6PD rapid test (G6PD Rapid 
Test CARESTART, Access Bio, USA). G6PD wild type 
patients were treated with a single dose of primaquine 
(0.25  mg/kg, REMEDICA, Cyprus). Patients were fol-
lowed up 28  days (D28) after their initiation of treat-
ment to establish treatment effectiveness, using the 
same qPCR technique as in the prevalence survey. D28 
was chosen instead of D42 (traditional endpoint when 
using microscopy), to detect parasitological failures early 
enough and avoid transmission to the community of 
resistant parasites. Patients with D28 sustained parasi-
taemia were offered atovaquone-proguanil (Malarone®, 
GlaxoSmithKline, Belgium) as second-line treatment. 
G6PD screening, Primaquine treatment and D28 follow-
up were implemented mid-December 2014.
A case investigation form (CIF) was completed by the 
MSF team for each confirmed malaria case (adapted 
from the WHO [15]). The CIF included demographic 
information and other characteristics, a history of the 
current illness including diagnostic test results and treat-
ment, travel history, and possible mode of transmission.
Testing, DHA–PPQ treatment, and training on case 
management were provided by the public and private 
sectors. G6PD testing, primaquine treatment, and D28 
follow-up were implemented by MSF teams. Health pro-
motion messages were provided both by the public and 
private sectors and MSF teams.
Statistical analysis
Prevalence calculations were conducted using sampling 
weights (W), calculated using village size (N) and number 
of respondents in each village (n) as follows: W = N/n. 
For prevalence at district level, the village was specified 
as sampling strata and a calibration adjustment was per-
formed using a logit method [16]. The population cen-
sus done in June 2014 was used and calibration variables 
were sex and age category (0–4, 5–14, 15–34, 35–65, 65–
Inf). Considering the criteria for eligibility, the sample 
design and the calibration adjustment, the study popula-
tion at the district level was estimated as representative 
of the population living in Chey Saen district. Confidence 
interval calculations used the scaled Chi squared distri-
bution for the log likelihood from a binomial distribution 
[17]. District and village prevalence are presented with 
their 95  % confidence interval. Statistical analyses were 
conducted using R version 3.1.1 (R Development Core 
Team, 2014).
For PCD, the main outcomes were the monthly number 
of screened cases and confirmed P. falciparum (mono-
infections and mixed infections) cases and the annual 
number of individuals treated per village, per month and 
per provider type. Incidences per village were calculated 
per year and per 1000 inhabitants using data from popu-
lation census. Monthly incidences were calculated at dis-
trict level.
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Out of 2971 selected villagers, 2088 agreed and took 
part in the survey. The response rate per village ranged 
from 43 to 95  % (Fig.  1). At district level, males aged 
15–34 years had the lowest (56 %) response rate, on the 
contrary women aged 15–34  years had the highest one 
(77  %). Reasons for non-response are summarized in 
Table  1, with “absence” (to the rice field, to the forest, 
travel, etc.) accounting for 53  % of the non-responses. 
Exclusion represented less than 5  %, and concerned 
mainly villagers who were too young or were sick at the 
moment of the survey. Overall, the age and gender dis-
tribution of the study participants was similar to that of 
the district population (Fig. 2), with mainly 1–4 year old 
respondents being under-represented (7.7 % in respond-
ent vs 11.1 % in the district population).
Prevalence survey—results
Of the 2088 samples, four were coagulated before prep-
aration and could not be analysed. 76 of the 2084 par-
ticipants were screened positive as Plasmodium spp. 
carrier, resulting in a prevalence of 3.73  % [2.91; 4.68] 
after adjusting for village size (weighting); village prev-
alence ranged from 0 to 12.1  % [6.4; 20.0] (Table  2). 
No specific trend was found for the geographical 
distribution (Fig.  3). Five participants had fever (body 
temperature >37.5 °C) with a negative RDT. All positive 
cases were treated with a three-day course of DHA–
PPQ and primaquine for G6PD wild type patients: para-
sitaemia at 28 days post-treatment was negative for all 
individuals. 
Following species determination, P. falciparum (mono 
and mixed infections) was identified in 16 participants, 
giving a prevalence of 0.74  % [0.41; 1.21] after weight-
ing the villages. Village prevalence ranged from 0 to 
4.6  % [1.4; 10.5] (Table  2). Median parasitaemia was 
30,142 p/ml (IQR: 578,839). Six of the eight villages 
with presence of P. falciparum were located in the East 
of the district, and five of them were in the same area 
and were geographically connected (Fig. 3). Seventy five 
percent (8/12) of P. falciparum carriers identified were 
male. Plasmodium falciparum was not found in the 
age groups of 0–4  years and 65+  years; the 15–34 age 
group accounted for a half of the total number of cases 
(Table 3).
Plasmodium vivax (mono and mixed infections) 
was identified in 26 participants, giving a prevalence of 
1.33 % [0.85; 1.97], and ranging from 0 to 3.6 % [0.9; 9.3] 
between villages (Table  2); no geographical pattern was 
observed (Fig. 3). More than 75 % (20/26) of P. vivax car-
riers identified were male. P. vivax was found in all age 
groups, with more than a half in the 15–34  years age 
group. In 37 Plasmodium spp. carriers (48.7  %), species 
determination could not be conducted due to insufficient 
genetic material (too low parasitaemia).
Of the 16 P. falciparum samples, in 11 sufficient k13 
gene was amplified by PCR for subsequent sequencing. 
The mutant-type allele (C580Y) was found in six sam-
ples (55  %). This indication of resistance to artemisinin 
was found in the Eastern (Chamreun, Chrach, Ploach and 
Phneak Roleuk) and Western (Kouk and Samroang) parts 
of the district.Fig. 1 Response rate by village in the prevalence survey





Left after entry point 8 0.9
Moved 44 4.9
Name unknown 75 8.4
Reason not available 34 3.8
Refusal 210 23.4
Wrong location 11 1.2
Total 897 100.0
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Passive case detection
At district level, 3007 villagers (13.5  % of the popula-
tion) were screened for malaria during the study period 
(Table 4). Most screening was provided by village malaria 
workers (2269; 75.5 %), followed by health facilities (397; 
13.3  %) and registered private providers (290; 9.6  %). 
The surveillance system identified 157 cases of P. falci-
parum mono-infection and 213 cases of mixed infec-
tion. The total of P. falciparum (mono-infections plus 
mixed infections) was 370 cases. This gave an annual 
incidence of P. falciparum of 16.8 cases per 1000 inhab-
itants in the district. Village incidence ranged from 
1.3/1000 inhabitants in Bor to 54.9/1000 inhabitants in 
Srae Veal (Fig. 4). Seven villages had an incidence higher 
than 20/1000 inhabitants: all were located in the Eastern 
part of the district and could be considered as two geo-
graphically connected clusters. The 1st cluster included 
Chamreun (Incidence = 54.3), Chrach (I = 40.7), Pakde-
voat (I = 27.5), Thmea (I = 26.1) and Ploach (I = 20.7). 
The 2nd cluster included Srae Veal (I  =  54.9) and 
Pheak Roleuk (I = 28.5). Most P. falciparum cases were 
male, and more than half of all cases belonged to the 
15–34 years age group (Table 5).  
Analysis of monthly incidence identified a high trans-
mission season from September to January. June to 
August incidence was around 0.7/1000 per month, 
September to December incidence ranged from 2.2 to 
3.6/1000 per month, and February to May incidence 
ranged from 0.2 to 0.6/1000 per month (Fig. 5). 149 vil-
lagers had blood taken 28  days after case notification, 
to establish treatment effectiveness. 52 of these samples 
(34.9 %) were still positive at day 28 by qPCR (Table 6).
223 CIF of P. falciparum (mono and mixed infections) 
cases were available for analysis. The occupation of most 
cases was farmer (175, 78.5  %); most spent at least one 
night in forest, field or plantation the month preceding 
blood sampling (197, 88.3 %). Almost 50 % of these for-
ests, fields and plantations were located in the Eastern 
part of the district (areas with high prevalence and inci-
dence) around the villages of Thmea (41 cases, 21.8  %) 
and Chrach (32 cases, 16.2 %), and the bordering Stung 
Treng province (22 cases, 11.2 %).
Discussion
The primary objectives of this study were to estimate the 
prevalence of Plasmodium spp. and P. falciparum at dis-
trict and village level in Chey Saen district and to com-
pare this with the incidence reported through the passive 
case detection system. At the same period of the year 
(September and October), the prevalence of Plasmodium 
spp. was slightly elevated (from 2.61 to 3.73) compared to 
the findings of a survey conducted in 2013 [18].
Despite the fact that the current survey relied on PCR 
testing of high blood volume, which is more sensitive 
than PCR from a filter paper dried blood spot (volume 
around 5 µl) as used in the 2013 survey, results showed 
a decrease at district level in the prevalence of P. falci-
parum (with a slight overlap of confidence intervals). 
Plasmodium falciparum prevalence remains low in Chey 
Saen district. Similar low prevalence and variation in the 
dynamic of transmission have also been observed, using 
this sensitive molecular method. For instance in Pailin 
[18], the prevalence of P. falciparum dropped from about 
2 % in June 2013 to much lower than 1 % in June 2014. 
[19]. In addition, MSF programme has been running in 
2014, focusing on P. falciparum cases management. The 
decrease in the ratio P. falciparum/P. vivax is typical in 
areas of pre-elimination when treatment programmes 
(with ACT) are correctly functioning for each malaria 
episode, without implementing a radical cure for patients 
with persistent P. vivax infections.
The study had a number of limitations. The prevalence 
survey was designed to estimate prevalence at village 
level and to capture all parasite carriers from a repre-
sentative sample, but a bias may have been introduced 
due to preferential absenteeism of the male young adult 
population (the most at risk sub-population). However, 
as characteristics of respondents in terms of gender and 
age category were close to district population, and age 
and gender-adjustment was performed, a sizeable under-
estimation of the true district prevalence was not antici-
pated. Likewise, while temporary workers living in the 
compound of private companies (i.e. plantations) were 
Fig. 2 Proportion of district population and participant in prevalence 
survey by gender and by age category
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not reachable, which may have led to an underestimation 
of the prevalence, this specific group was probably lim-
ited in size.
Overall, passive case detection and prevalence survey 
showed very similar results to the extent that the two 
geographical clusters with high number of cases were 
identified by both approaches. Six out of the seven vil-
lages with higher incidence were also identified through 
the prevalence survey, suggesting that villages with high 
incidence also had a sizeable asymptomatic reservoir. 
However, the prevalence survey failed to identify P. fal-
ciparum cases in 15 villages where cases were detected 
passively, and the village with highest malaria inci-
dence had no positive cases in the prevalence survey. 
This may be the consequence of the survey design, as it 
was not powered for detection of low prevalence at vil-
lage level as well as areas with specific and potentially 
limited in size at risk populations. Forest goers are also 
more likely to be out of the village during the survey. If 
parasite prevalence is indeed a better surveillance meas-
ure for elimination programs than numbers of sympto-
matic cases [20], surveys have to enroll high numbers of 
participants per geographical unit studied. This may ren-
der the monitoring of elimination interventions highly 
resource-demanding in low prevalence settings. Passive 
and active case detection (focusing on at-risk popula-
tions) may thus remain an important tool to monitor 
malaria elimination.
Results can suggest that transmission in the villages is 
limited. Discrepancies between incidence and prevalence 
might be partly explained by the absence of infected peo-
ple during the prevalence survey. Those who stay more 
permanently in the villages (hence more often included 
in the survey) would be less likely to be positive. In addi-
tion, prevalence of asymptomatic cases is either not 
detected in 15 villages, or very low in the seven others. 
Symptomatic patients may have been infected elsewhere 
(e.g. in the forest) and not through local transmission in 
the villages.
The distribution of positive P. falciparum cases per age 
group also suggests that infection occurs outside the vil-
lages: cases passively detected in the 0–4 age group repre-
sent 1.9 % of total cases (and 0 % in the prevalence survey), 
while children under five account for 11 % of the overall 
Table 2 Prevalence, 95 % confidence interval by malaria species and by village in the prevalence survey
a Including mixed infections of P. falciparum and P. vivax
Village P. falciparuma P. vivaxa Unspecified Total
Cases Prevalence [CI 95] Cases Prevalence [CI 95] Cases Prevalence [CI 95] Cases Prevalence [CI 95]
Bor 0 0.0 [0.0; 0.0] 3 3.4 [0.8; 8.7] 0 0.0 [0.0; 0.0] 3 3.4 [0.8; 8.7]
Chamreun 2 2.4 [0.4; 7.4] 3 3.6 [0.9; 9.3] 2 2.4 [0.4; 7.4] 7 8.4 [3.6;15.9]
Chrach 4 4.4 [1.3;10.1] 3 3.3 [0.8; 8.5] 5 5.5 [1.9;11.6] 11 12.1 [6.4;20.0]
Damnak Trach 0 0.0 [0.0; 0.0] 1 1.2 [0.1; 5.4] 0 0.0 [0.0; 0.0] 1 1.2 [0.1; 5.4]
Khyang 0 0.0 [0.0; 0.0] 1 1.1 [0.1; 4.8] 4 4.3 [1.3;10.0] 5 5.4 [1.9;11.5]
Kouk 1 1.1 [0.1; 4.8] 0 0.0 [0.0; 0.0] 2 2.2 [0.3; 6.7] 3 3.3 [0.8; 8.4]
Kravan 0 0.0 [0.0; 0.0] 0 0.0 [0.0; 0.0] 2 2.3 [0.4; 7.0] 2 2.3 [0.4; 7.0]
Meun reach 0 0.0 [0.0; 0.0] 0 0.0 [0.0; 0.0] 1 1.0 [0.1; 4.6] 1 1.0 [0.1; 4.6]
Pakdevoat 1 1.1 [0.1; 5.1] 0 0.0 [0.0; 0.0] 2 2.3 [0.4; 7.1] 3 3.4 [0.8; 8.9]
Peuk 0 0.0 [0.0; 0.0] 3 3.1 [0.8; 8.0] 3 3.1 [0.8; 8.0] 6 6.3 [2.5;12.4]
Phneak Roleuk 4 4.6 [1.4;10.5] 1 1.1 [0.1; 5.1] 3 3.4 [0.8; 8.9] 7 8.0 [3.5;15.2]
Ploach 1 1.1 [0.1; 4.9] 0 0.0 [0.0; 0.0] 1 1.1 [0.1; 4.9] 2 2.2 [0.4; 6.9]
Pramoul Phdom 0 0.0 [0.0; 0.0] 1 1.2 [0.1; 5.2] 0 0.0 [0.0; 0.0] 1 1.2 [0.1; 5.2]
Putrea 0 0.0 [0.0; 0.0] 1 1.1 [0.1; 4.7] 0 0.0 [0.0; 0.0] 1 1.1 [0.1; 4.7]
S’aang 0 0.0 [0.0; 0.0] 1 1.0 [0.1; 4.5] 4 4.1 [1.2; 9.4] 5 5.1 [1.8;10.8]
Samroang 1 1.1 [0.1; 4.9] 1 1.1 [0.1; 4.9] 1 1.1 [0.1; 4.9] 3 3.3 [0.8; 8.6]
Slaeng 0 0.0 [0.0; 0.0] 2 2.0 [0.3; 6.2] 0 0.0 [0.0; 0.0] 2 2.0 [0.3; 6.2]
Srae veal 0 0.0 [0.0; 0.0] 2 2.3 [0.4; 7.0] 3 3.4 [0.8; 8.8] 5 5.7 [2.0;12.0]
Tasu 0 0.0 [0.0; 0.0] 0 0.0 [0.0; 0.0] 0 0.0 [0.0; 0.0] 0 0.0 [0.0; 0.0]
Teuk Lich 0 0.0 [0.0; 0.0] 0 0.0 [0.0; 0.0] 1 1.2 [0.1; 5.4] 1 1.2 [0.1; 5.4]
Thmea 2 2.1 [0.3; 6.5] 2 2.1 [0.3; 6.5] 1 1.1 [0.1; 4.7] 4 4.2 [1.3; 9.7]
Thmei 0 0.0 [0.0; 0.0] 1 1.3 [0.1; 5.6] 0 0.0 [0.0; 0.0] 1 1.3 [0.1; 5.6]
Tuol Peuk 0 0.0 [0.0; 0.0] 0 0.0 [0.0; 0.0] 2 2.1 [0.3; 6.5] 2 2.1 [0.3; 6.5]
District 16 0.74 [0.41; 1.21] 26 1.33 [0.85; 1.97] 37 1.84 [1.28; 2.54] 76 3.73 [2.91; 4.68]
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population. Young children are staying most of the time 
inside the villages, as they are indeed less susceptible to 
accompany adults outside. Finally the fact that 85.9 % of P. 
falciparum cases were men (and 54.3 % in the 15–34 age 
group), is also an indication of limited village transmission: 
women are well known to stay much more inside the vil-
lage (despite not to the extent of young children). This pos-
sible transmission pattern outside of the villages should be 
confirmed with further studies as this has a direct impact 
on elimination strategies, particularly on vector control.
Fig. 3 Geographic distribution of a all cases, b Pf‑Mix cases, c Pv cases, d unspecified specie cases in the prevalence survey
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Amongst the 16 P. falciparum positive samples of this 
survey, only 11 could be screened for mutations (indicat-
ing artemisinin resistance), and six (55 %) presented the 
mutant-type k13 allele (C580Y) closely associated with 
artemisinin resistance. Asymptomatic individuals could 
thus be an additional reservoir for artemisinin resistance. 
Cases were found both in Eastern and Western part of 
the district, which means that k13 resistance-associated 
mutations are not confined to a limited area. This result 
was in accordance with the findings of the 2013 survey 
(seven P. falciparum samples out of 11–64  %-presented 
the mutant-type k13 allele), and suggests artemisinin 
resistance is a public health threat in Chey Saen district 
(realizing the absolute figures remain low). An additional 
reason for concern is the analysis of the treatment effi-
cacy for symptomatic cases, with more than a third of 
all cases still positive with PCR 28 days after administra-
tion of first-line treatment. While poor treatment adher-
ence and poor drug quality/storage conditions cannot be 
excluded in this study, recent drug efficacy studies using 
Table 3 Number and percentage of cases by species and by gender and age category in the prevalence survey
a Including mixed infections of P. falciparum and P. vivax
Female Male Total
N % N % N %
P. falciparuma
 0–4 0 0.0 0 0.0 0 0.0
 5–14 1 6.3 1 6.3 2 12.5
 15–34 3 18.8 5 31.3 8 50.0
 35–64 0 0.0 6 37.5 6 37.5
 >64 0 0.0 0 0.0 0 0.0
 Total 4 25.0 12 75.0 16 100.0
P. vivaxa
 0–4 1 3.8 0 0.0 1 3.8
 5–14 2 7.7 2 7.7 4 15.4
 15–34 3 11.5 11 42.3 14 53.8
 35–64 0 0.0 6 23.1 6 23.1
 >64 0 0.0 1 3.8 1 3.8
 Total 6 23.1 20 76.9 26 100.0
P. unspecified
 0–4 0 0.0 0 0.0 0 0.0
 5–14 1 2.7 3 8.1 4 10.8
 15–34 5 13.5 13 35.1 18 48.6
 35–64 7 18.9 6 16.2 13 35.1
 >64 2 5.4 0 0.0 2 5.4
 Total 15 40.5 22 59.5 37 100.0
All species
 0–4 1 1.3 0 0.0 1 1.3
 5–14 4 5.3 6 7.9 10 13.2
 15–34 11 14.5 27 35.5 38 50.0
 35–64 7 9.2 17 22.4 24 31.6
 >64 2 2.6 1 1.3 3 3.9
 Total 25 32.9 51 67.1 76 100.0
Table 4 Number of  villagers screened and  positivity rate 
per provider type
Provider Screened Pf Positivity 
rate
N %
Health center 188 6.3 50 26.6
Health post 209 7.0 36 17.2
MSF 50 1.7 4 8.0
Private 290 9.6 49 16.9
VMW 2269 75.5 231 10.2
Total 3007 100.0 370 12.3
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the standard WHO therapeutic efficacy study protocol 
for symptomatic cases have recently observed similar 
high treatment failure rates in two provinces border-
ing Preah Vihear province, with an adequate clinical and 
parasitological response at D42 in Siem Reap of 37.5  % 
and in Stung Treng of 66.7 % (Results from ‘TES and K13 
Surveillance’, CNM, presentation at Malaria Elimination 
Partners Convening—May 2015).
Overall these results highlight the low effectiveness of 
DHA–PPQ as first-line treatment in many parts of Cam-
bodia, and that resistance/treatment failure has been 
moving from the ‘classical’ Western Thai-Cambodian 
border area towards the Northern area. The findings of 
this study indicate that DHA–PPQ may no longer be 
effective for symptomatic cases with high parasitaemia. 
This may be due to resistance to artemisinin, as well as 
Fig. 4 Comparison of P. falciparum incidence and prevalence per village
Table 5 Number of Plasmodium falciparum cases by gender and by age category in PCD
Female Male Total
N % N % N %
0–4 3 0.8 4 1.1 7 1.9
5–14 12 3.2 31 8.4 43 11.6
15–34 11 3.0 201 54.3 212 57.3
35–64 23 6.2 79 21.4 102 27.6
>64 3 0.8 3 0.8 6 1.6
All 52 14.1 318 85.9 370 100.0
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to the piperaquine partner drug [21–24]. On the other 
hand, D28 on asymptomatic cases identified through the 
prevalence survey were all undetectable, suggesting that 
clearance of low parasitaemias in asymptomatic carriers 
was still achieved with this drug combination. To dem-
onstrate however full efficacy on asymptomatic carriers, 
a longer follow up would be necessary in a larger sam-
ple size. This is important for the choice of anti-malarial 
treatment in mass drug administrations, aimed to target 
the asymptomatic reservoir.
These data illustrate the importance of using highly 
sensitive diagnostic tools to identify the asymptomatic 
carriers. They invite to take action against this reservoir, 
which contribute to maintaining transmission.
They also show big variations between villages, justify-
ing different type of interventions (in addition to good 
traditional control programmes) depending on the levels 
of prevalence and incidence: active case detection aim-
ing at profiling and targeting at risk people, reactive case 
detection (whose positivity rate is higher than passive case 
detection in the area), or targeted malaria treatment with 
mass drug administration proposed to certain groups.
Conclusions
The overall low prevalence of Plasmodium spp. and P. 
falciparum in Chey Saen district in Cambodia was con-
firmed by the prevalence survey, while there were impor-
tant variations between villages. Symptomatic cases had 
a different pattern and were likely acquired outside the 
villages. It illustrates the importance of prevalence sur-
veys in targeting interventions for elimination. Mutations 
in the k13-propeller domain gene (C580Y), conferring 
artemisinin resistance, were highly prevalent in both 
symptomatic and asymptomatic cases, indicating its sig-
nificance in Chey Saen district (realizing the absolute 
figures remain low). Asymptomatic individuals could be 
an additional reservoir for artemisinin resistance. The 
low effectiveness of DHA–PPQ for symptomatic cases 
indicates that PPQ is no longer able to complement the 
reduced potency of DHA to treat falciparum malaria and 
highlights the need for an alternative first-line treatment.
Fig. 5 Monthly incidence for P. falciparum
Table 6 D28 results in PCD and prevalence survey
Negative Positive Total
N % N % N %
November 10 35.7 18 64.3 28 100
December 40 72.7 15 27.3 55 100
January 38 79.2 10 20.8 48 100
February 6 50.0 6 50.0 12 100
March 3 50.0 3 50.0 6 100
All 97 65.1 52 34.9 149 100
Prevalence survey 48 100 0 0.0 0 0
Page 11 of 11Falq et al. Malar J  (2016) 15:446 
Abbreviations
PCR: polymerase chain reaction; DHA–PPQ: dihydroartemisinin–piperaquine; 
RDT: rapid diagnostic test; ACT: artemisinin‑based combination therapy; PCD: 
passive case detection; EDTA: ethylenediamine tetraacetic acid; DNA: deoxyri‑
bonucleic acid; RNA: ribonucleic acid; pLDH/HRP2: parasite lactate dehydro‑
genase/histidine‑rich protein‑2; G6PD: glucose‑6‑phosphate dehydrogenase 
deficiency; CIF: case investigation form; WHO: World Health Organization; 
VMW: village malaria workers.
Authors’ contributions
JMK, MDS, RVDB, AD, WE and CN conceived and designed the study; GF 
organized, facilitated and supervised the acquisition of data in Cambodia; GF 
performed the statistical analysis; MI carried out the laboratory analysis; All 
authors participated in the interpretation of the results; GF and JMK wrote the 
paper; MDS, RVDB and AD revised the manuscript for substantial intellectual 
content; All authors read and approved the final manuscript.
Author details
1 Médecins Sans Frontières, 46, rue de l’Arbre Bénit, 1050 Brussels, Belgium. 
2 Médecins Sans Frontières, 68, rue de Gasperich, 1617 Luxembourg City, 
Luxembourg. 3 Centre for Parasitology, Entomology and Malaria Control, 477 
Betong Street, Village Trapangsvay, Sanakat Phnom Penh Thmey, Khan Sen 
Sok, Phnom Penh, Cambodia. 4 Department of Molecular Tropical Medicine 
and Genetics, Faculty of Tropical Medicine, Mahidol University, 3/F, 60th Anni‑
versary Chalermprakiat Building, 420/6 Rajvithi Road, Bangkok 10400, Thailand. 
5 Mahidol Oxford Tropical Research Unit, Faculty of Tropical Medicine, Mahidol 
University, Bangkok, Thailand. 
Acknowledgements
This study was sponsored by Médecins Sans Frontières, Belgium. Dr. KhoyBun 
Thanny, Director of Preah Vihear Provincial Health Department, Cambodia, 
is acknowledged for authorizing this study. We are thankful to Jean‑Philippe 
Dousset, Lieven Vernaeve and Mark Debackere for their support and relevant 
advice. We would also like to thank the study teams, MSF field team and the 
villagers who took part in this study.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets during and/or analysed during the current study available from 
the corresponding author on reasonable request.
Ethical approval and consent to participate
Individual written consent was obtained before inclusion in the prevalence 
survey and for all components of the MSF program not included in the 
national guideline. Ethical approval was granted by the Cambodian National 
Ethics Committee for Health Research (280 NECHR) and the Ethics Review 
Board of Médecins Sans Frontières (ID1401).
Funding
Funding was provided by Médecins Sans Frontières.
Received: 1 June 2016   Accepted: 11 August 2016
References
 1. WHO. World malaria report. Geneva: World Health Organization; 2013. 
http://www.who.int/malaria/publications/world_malaria_report_2013/
en/. Accessed 23 Aug 2016.
 2. WHO. Global plan for artemisinin resistance containment. Geneva: World 
Health Organization; 2011. http://www.who.int/malaria/publications/atoz/
artemisinin_resistance_containment_2011.pdf. Accessed 23 Aug 2016.
 3. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Don‑
dorp AM, et al. The last man standing is the most resistant: eliminating 
artemisinin‑resistant malaria in Cambodia. Malar J. 2009;8:31.
 4. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White 
MJ, et al. The potential contribution of mass treatment to the control of 
Plasmodium falciparum malaria. PLoS One. 2011;6:e20179.
 5. Stresman G, Kobayashi T, Kamanga A, Thuma PE, Mharakurwa S, Moss 
WJ, et al. Malaria research challenges in low prevalence settings. Malar J. 
2012;11:353.
 6. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence 
of artemisinin‑resistant malaria in western Cambodia. N Engl J Med. 
2008;359:2619–20.
 7. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Arte‑
misinin resistance in Plasmodium falciparum malaria. N Engl J Med. 
2009;361:455–67.
 8. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, 
et al. Artemisinin‑resistant Plasmodium falciparum in Pursat province, 
western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 
2012;12:851–8.
 9. WHO. Global report on antimalarial drug efficacy and drug resistance 
2000–2010. Geneva: World Health Organization; 2010.
 10. WHO. Artemisinin and artemisinin‑based combination therapy resistance. 
Geneva: World Health Organization; 2016.
 11. Imwong M, Hanchana S, Malleret B, Renia L, Day NPJ, Dondorp A, et al. 
High‑throughput ultrasensitive molecular techniques for quantifying 
low‑density malaria parasitemias. J Clin Microbiol. 2014;52:3303–9.
 12. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A‑C, Khim N, 
et al. A molecular marker of artemisinin‑resistant Plasmodium falciparum 
malaria. Nature. 2014;505:50–5.
 13. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. 
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl 
J Med. 2014;371:411–23.
 14. Manske M, Miotto O, Campino S, Auburn S, Almagro‑Garcia J, Maslen G, 
et al. Analysis of Plasmodium falciparum diversity in natural infections by 
deep sequencing. Nature. 2012;487:375–9.
 15. WHO. Disease surveillance for malaria control: an operation manual. 
Geneva: World Health Organization; 2012.
 16. Deville JC, Sarndal CE, Sautory O. Generalized raking procedures in survey 
sampling. J Am Stat Assoc. 1993;88:1013–20.
 17. Rao JNK, Scott AJ. On Chi squared tests for multiway contingency 
tables with cell proportions estimated from survey data. Ann Stat. 
1984;12:46–60.
 18. Bosman P, Stassijns J, Nackers F, Canier L, Kim N, Khim S, et al. Plasmodium 
prevalence and artemisinin‑resistant falciparum malaria in Preah Vihear Prov‑
ince, Cambodia: a cross‑sectional population‑based study. Malar J. 2014;13:394.
 19. Tripura R, Peto TJ, Chalk J, Lee SJ, Sirithiranont P, Nguon C, et al. Persistent 
Plasmodium falciparum and Plasmodium vivax infections in a western 
Cambodian population: implications for prevention, treatment and 
elimination strategies. Malar J. 2016;15:181.
 20. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, et al. Optimising 
strategies for Plasmodium falciparum malaria elimination in Cambodia: 
primaquine, mass drug administration and artemisinin resistance. PLoS 
One. 2012;7:e37166.
 21. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. 
Dihydroartemisinin–piperaquine failure associated with a triple mutant 
including kelch13 C580Y in Cambodia: an observational cohort study. 
Lancet Infect Dis. 2015;15:683–91.
 22. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sun‑
drakes S, et al. Ex vivo drug susceptibility testing and molecular profiling 
of clinical Plasmodium falciparum isolates from Cambodia from 2008 
to 2013 suggest emerging piperaquine resistance. Antimicrob Agents 
Chemother. 2015;59:4631–43.
 23. Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence 
of Plasmodium falciparum malaria multidrug resistance to artemisinin 
and piperaquine in Western Cambodia: dihydroartemisinin–piperaquine 
open‑label multicenter clinical assessment. Antimicrob Agents Chem‑
other. 2015;59:4719–26.
 24. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroar‑
temisinin–piperaquine resistance in Plasmodium falciparum malaria 
in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 
2016;3:357–65.
